# Seaport Therapeutics, Inc.: overview

SPTX · Nasdaq · CIK 2042347 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sptx.md) · [Financials](/companies/sptx/financials.md) · [Filings](/companies/sptx/filings.md) · [Insiders](/companies/sptx/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(5.65)](/filings/0001193125-26-260678.md) | [(6.40)](/filings/0001193125-26-329537.md) | [(10.34)](/filings/0001193125-26-260678.md) | [(1.78)](/filings/0001193125-26-329537.md) |
| Free cash flow | $m | [(20.3)](/filings/0001193125-26-260678.md) | [(15.6) d](/filings/0001193125-26-329537.md) | [(20.2)](/filings/0001193125-26-260678.md) | [(26.1) d](/filings/0001193125-26-329537.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure.

## Last five fiscal years

Not reported.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sptx/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [ARCH Venture Management, LLC](/funds/1274403.md) | 2026-06-30 | $136.6m | 6,294,951 |  | New +6,294,951 |
| [GENERAL ATLANTIC, L.P.](/funds/1017645.md) | 2026-06-30 | $132.5m | 6,101,582 |  | New +6,101,582 |
| [Sofinnova Investments, Inc.](/funds/1631134.md) | 2026-06-30 | $77.4m | 3,564,871 |  | New +3,564,871 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $47.3m | 2,178,642 |  | New +2,178,642 |
| [TRV GP VI, LLC](/funds/1990716.md) | 2026-06-30 | $44.8m | 2,061,222 |  | New +2,061,222 |
| [CANADA PENSION PLAN INVESTMENT BOARD](/funds/1283718.md) | 2026-06-30 | $42.9m | 1,975,791 |  | New +1,975,791 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $40.9m | 1,815,845 |  | New +1,815,845 |
| [Foresite Capital Management VI LLC](/funds/2013341.md) | 2026-06-30 | $38.7m | 1,779,521 |  | New +1,779,521 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $25.7m | 1,185,100 |  | New +1,185,100 |
| [Bellevue Group AG](/funds/1674546.md) | 2026-06-30 | $23.9m | 1,100,000 |  | New +1,100,000 |

## Recent filings

[All 54 filings](/companies/sptx/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-03 | 07:11 ET | [10-Q](/filings/0001193125-26-329537.md) | Quarterly report, period 2026-06-30 | 0001193125-26-329537 |
| 2026-08-03 | 07:03 ET | [8-K](/filings/0001193125-26-329528.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-329528 |
| 2026-06-08 | 07:15 ET | [10-Q](/filings/0001193125-26-260678.md) | Quarterly report, period 2026-03-31 | 0001193125-26-260678 |
| 2026-06-08 | 07:11 ET | [8-K](/filings/0001193125-26-260671.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-260671 |
| 2026-05-11 | 19:54 ET | [SCHEDULE 13D](/filings/0000950142-26-001350.md) | Ownership report, active investor | 0000950142-26-001350 |
| 2026-05-06 | 16:26 ET | [SCHEDULE 13D](/filings/0001193125-26-209100.md) | Ownership report, active investor | 0001193125-26-209100 |
| 2026-05-04 | 16:28 ET | [8-K](/filings/0001193125-26-204086.md) | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-26-204086 |
| 2026-04-27 | 06:06 ET | [S-1/A](/filings/0001193125-26-178716.md) | Registration statement, amended | 0001193125-26-178716 |
| 2026-04-10 | 16:01 ET | [S-1](/filings/0001193125-26-151211.md) | Registration statement | 0001193125-26-151211 |

## Latest annual report

No annual report is in coverage.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 2042347
- Tickers: SPTX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.